{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:18:03Z","timestamp":1795029483085,"version":"4.10.2"},"reference-count":94,"publisher":"American Association for Cancer Research (AACR)","issue":"20","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"HonorHealth"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor treating fields (TTFields), a new modality of cancer treatment, are electric fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment of glioblastoma multiforme and mesothelioma, and they are currently under study in many other cancer types. While antimitotic effects were the first recognized biological anticancer activity of TTFields, data have shown that tumor treating fields achieve their anticancer effects through multiple mechanisms of action. TTFields therefore have the ability to be useful for many cancer types in combination with many different treatment modalities. Here, we review the current understanding of TTFields and their mechanisms of action.<\/jats:p>","DOI":"10.1158\/0008-5472.can-22-0887","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T13:54:56Z","timestamp":1657893296000},"page":"3650-3658","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["The Mechanisms of Action of Tumor Treating Fields"],"prefix":"10.1158","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-6759","authenticated-orcid":false,"given":"Justin C.","family":"Moser","sequence":"first","affiliation":[{"name":"1HonorHealth Research and Innovation Institute, Scottsdale, Arizona."},{"name":"2Department of Medicine, University of Arizona College of Medicine- Phoenix, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2127-4548","authenticated-orcid":false,"given":"Ellaine","family":"Salvador","sequence":"additional","affiliation":[{"name":"3Section Experimental Neurosurgery, Department of Neurosurgery, University of W\u00fcrzburg, W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Deniz","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Division of Hematology Oncology and Transplant, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Swanson","sequence":"additional","affiliation":[{"name":"5Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9976-0429","authenticated-orcid":false,"given":"Jack","family":"Tuszynski","sequence":"additional","affiliation":[{"name":"6Department of Physics, University of Alberta, Edmonton, Alberta, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen W.","family":"Carlson","sequence":"additional","affiliation":[{"name":"7Department of Neurosurgery, Beth Israel Deaconess Medical Center\/Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimha Kumar","family":"Karanam","sequence":"additional","affiliation":[{"name":"8Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0787-0634","authenticated-orcid":false,"given":"Chirag B.","family":"Patel","sequence":"additional","affiliation":[{"name":"9Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston Texas."},{"name":"10Neuroscience and Cancer Biology Graduate Programs, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-4169","authenticated-orcid":false,"given":"Michael","family":"Story","sequence":"additional","affiliation":[{"name":"8Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1386","authenticated-orcid":false,"given":"Emil","family":"Lou","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Division of Hematology Oncology and Transplant, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9759-8149","authenticated-orcid":false,"given":"Carsten","family":"Hagemann","sequence":"additional","affiliation":[{"name":"3Section Experimental Neurosurgery, Department of Neurosurgery, University of W\u00fcrzburg, W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"2025112417240608100_bib1","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112417240608100_bib2","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"key":"2025112417240608100_bib3","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/ijerph13111128","article-title":"An overview of Sub-cellular mechanisms involved in the action of TTFields","volume":"13","author":"Tuszynski","year":"2016","journal-title":"Int J Environ Res Public Health"},{"key":"2025112417240608100_bib4","doi-asserted-by":"crossref","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells","volume":"5","author":"Giladi","year":"2015","journal-title":"Sci Rep"},{"key":"2025112417240608100_bib5","doi-asserted-by":"crossref","first-page":"e0125269","DOI":"10.1371\/journal.pone.0125269","article-title":"Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit","volume":"10","author":"Gera","year":"2015","journal-title":"PLoS One"},{"key":"2025112417240608100_bib6","article-title":"Optimizing Characteristic of an Electric Field to Increase the Field's Effect on Proliferating Cells","author":"Palti","year":"2011","journal-title":"USPTO, Editor Standen Ltd"},{"key":"2025112417240608100_bib7","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1088\/0031-9155\/59\/15\/4137","article-title":"Predicting the electric field distribution in the brain for the treatment of glioblastoma","volume":"59","author":"Miranda","year":"2014","journal-title":"Phys Med Biol"},{"key":"2025112417240608100_bib8","doi-asserted-by":"crossref","first-page":"E483","DOI":"10.1016\/j.ijrobp.2019.06.1376","article-title":"Efficacy and thermal safety of tumor treating fields delivered to the thorax: a simulation-based study","volume":"105","author":"Bomzon","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112417240608100_bib9","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/ijc.30406","article-title":"Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo","volume":"139","author":"Voloshin","year":"2016","journal-title":"Int J Cancer"},{"key":"2025112417240608100_bib10","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1158\/1538-7445.AM2018-3204","article-title":"Transducer array configuration optimization for treatment of pancreatic cancer using Tumor Treating Fields (TTFields)","volume":"78","author":"Naveh","year":"2018","journal-title":"Cancer Res"},{"key":"2025112417240608100_bib11","doi-asserted-by":"crossref","first-page":"670809","DOI":"10.3389\/fonc.2021.670809","article-title":"Safety of Tumor Treating Fields (TTFields) Applied to the Torso","volume":"11","author":"Blatt","year":"2021","journal-title":"Front Oncol"},{"key":"2025112417240608100_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"2025112417240608100_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2025112417240608100_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pharmthera.2017.02.007","article-title":"Anti-mitotic agents: Are they emerging molecules for cancer treatment?","volume":"173","author":"Penna","year":"2017","journal-title":"Pharmacol Ther"},{"key":"2025112417240608100_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/mi.11.2.12","article-title":"Spindle poisons and cell fate: a tale of two pathways","volume":"11","author":"Matson","year":"2011","journal-title":"Mol Interv"},{"key":"2025112417240608100_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bcp.13126","article-title":"Microtubule destabilising agents: far more than just antimitotic anticancer drugs","volume":"83","author":"Bates","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025112417240608100_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15384101.2018.1559557","article-title":"Mitotic slippage: an old tale with a new twist","volume":"18","author":"Sinha","year":"2019","journal-title":"Cell Cycle"},{"key":"2025112417240608100_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrm929","article-title":"The spindle checkpoint: structural insights into dynamic signalling","volume":"3","author":"Musacchio","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025112417240608100_bib19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrm2163","article-title":"The spindle-assembly checkpoint in space and time","volume":"8","author":"Musacchio","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025112417240608100_bib20","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/jnci\/djt168","article-title":"Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs","volume":"105","author":"Tannous","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2025112417240608100_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pan.2013.11.009","article-title":"Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields","volume":"14","author":"Giladi","year":"2014","journal-title":"Pancreatology"},{"key":"2025112417240608100_bib22","doi-asserted-by":"crossref","first-page":"62267","DOI":"10.18632\/oncotarget.11407","article-title":"Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"2025112417240608100_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41420-018-0079-9","article-title":"Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition","volume":"4","author":"Kessler","year":"2018","journal-title":"Cell Death Discov"},{"key":"2025112417240608100_bib24","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1038\/s41598-019-43621-9","article-title":"Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase\/cytokinesis","volume":"9","author":"Berkelmann","year":"2019","journal-title":"Sci Rep"},{"key":"2025112417240608100_bib25","doi-asserted-by":"crossref","first-page":"e02","DOI":"10.1371\/journal.pone.0202141","article-title":"Tubulin's response to external electric fields by molecular dynamics simulations","volume":"13","author":"Timmons","year":"2018","journal-title":"PLoS One"},{"key":"2025112417240608100_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000469690","article-title":"Alternating electric fields therapy for malignant gliomas: from bench observation to clinical reality","volume":"32","author":"Wong","year":"2018","journal-title":"Prog Neurol Surg"},{"key":"2025112417240608100_bib27","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1126\/science.1106823","article-title":"A mitotic septin scaffold required for mammalian chromosome congression and segregation","volume":"307","author":"Spiliotis","year":"2005","journal-title":"Science"},{"key":"2025112417240608100_bib28","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1109\/TBME.2020.2965883","article-title":"A theoretical study on the biophysical mechanisms by which tumor treating fields affect tumor cells during mitosis","volume":"67","author":"Li","year":"2020","journal-title":"IEEE Trans Biomed Eng"},{"key":"2025112417240608100_bib29","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0006-291X(88)81306-8","article-title":"Fast disassembly of microtubules induced by Mg2+ or Ca2+","volume":"155","author":"Gal","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"2025112417240608100_bib30","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1083\/jcb.105.5.2137","article-title":"Free calcium increases during anaphase in stamen hair cells of Tradescantia","volume":"105","author":"Hepler","year":"1987","journal-title":"J Cell Biol"},{"key":"2025112417240608100_bib31","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1038\/s41388-019-0882-7","article-title":"Tumor-treating fields induce autophagy by blocking the Akt2\/miR29b axis in glioblastoma cells","volume":"38","author":"Kim","year":"2019","journal-title":"Oncogene"},{"key":"2025112417240608100_bib32","doi-asserted-by":"crossref","first-page":"e2753","DOI":"10.1038\/cddis.2017.171","article-title":"Biological activity of tumor-treating fields in preclinical glioma models","volume":"8","author":"Silginer","year":"2017","journal-title":"Cell Death Dis"},{"key":"2025112417240608100_bib33","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","article-title":"Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy","volume":"69","author":"Voloshin","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2025112417240608100_bib34","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.3390\/ijms19113684","article-title":"Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy","volume":"19","author":"Jo","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025112417240608100_bib35","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41419-018-1085-9","article-title":"AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)","volume":"9","author":"Shteingauz","year":"2018","journal-title":"Cell Death Dis"},{"key":"2025112417240608100_bib36","doi-asserted-by":"crossref","first-page":"e2711","DOI":"10.1038\/cddis.2017.136","article-title":"Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines","volume":"8","author":"Karanam","year":"2017","journal-title":"Cell Death Dis"},{"key":"2025112417240608100_bib37","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of 'BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2025112417240608100_bib38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13014-017-0941-6","article-title":"Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells","volume":"12","author":"Giladi","year":"2017","journal-title":"Radiat Oncol"},{"key":"2025112417240608100_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2021.08.011","article-title":"Tumor treating fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models","volume":"160","author":"Mumblat","year":"2021","journal-title":"Lung Cancer"},{"key":"2025112417240608100_bib40","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1101\/gad.2053211","article-title":"Analysis of protein dynamics at active, stalled, and collapsed replication forks","volume":"25","author":"Sirbu","year":"2011","journal-title":"Genes Dev"},{"key":"2025112417240608100_bib41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccr.2012.05.015","article-title":"A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1\/2","volume":"22","author":"Schlacher","year":"2012","journal-title":"Cancer Cell"},{"key":"2025112417240608100_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2019.10.003","article-title":"Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy","volume":"217","author":"Karanam","year":"2020","journal-title":"Transl Res"},{"key":"2025112417240608100_bib43","article-title":"Abstract 3217: Newly identified role of tumor treating fields in DNA damage repair and replication stress pathways","volume":"38","author":"Karanam","year":"2018","journal-title":"Cancer Res"},{"key":"2025112417240608100_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3389\/fonc.2018.00451","article-title":"Molecular evolution of a glioblastoma controlled with tumor treating fields and concomitant temozolomide","volume":"8","author":"Robins","year":"2018","journal-title":"Front Oncol"},{"key":"2025112417240608100_bib45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10585-009-9262-y","article-title":"Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs","volume":"26","author":"Kirson","year":"2009","journal-title":"Clin Exp Metastasis"},{"key":"2025112417240608100_bib46","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2017.09.006","article-title":"Migrating into the tumor: a roadmap for T cells","volume":"3","author":"van der Woude","year":"2017","journal-title":"Trends Cancer"},{"key":"2025112417240608100_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2025112417240608100_bib48","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1126\/science.1224922","article-title":"An immunosurveillance mechanism controls cancer cell ploidy","volume":"337","author":"Senovilla","year":"2012","journal-title":"Science"},{"key":"2025112417240608100_bib49","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1080\/09553002.2020.1837984","article-title":"An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications","volume":"97","author":"Karanam","year":"2021","journal-title":"Int J Radiat Biol"},{"key":"2025112417240608100_bib50","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-1707","article-title":"Abstract 1707: Tumor treating fields exert cellular and immunologic effects","volume":"78","author":"Wong","year":"2018","journal-title":"Cancer Res"},{"key":"2025112417240608100_bib51","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-1305","article-title":"Tumor treating fields (TTFields) promote a pro-inflammatory phenotype in macrophages","volume":"82","author":"Barsheshet","year":"2022","journal-title":"Cancer Res"},{"key":"2025112417240608100_bib52","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4049\/jimmunol.2100100","article-title":"T Cells retain pivotal antitumoral functions under Tumor-treating electric fields","volume":"207","author":"Diamant","year":"2021","journal-title":"J Immunol"},{"key":"2025112417240608100_bib53","doi-asserted-by":"crossref","first-page":"e149258","DOI":"10.1172\/JCI149258","article-title":"Tumor treating fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma","volume":"132","author":"Chen","year":"2022","journal-title":"J Clin Invest"},{"key":"2025112417240608100_bib54","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"2025112417240608100_bib55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neo.2020.11.003","article-title":"Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression","volume":"23","author":"Patel","year":"2021","journal-title":"Neoplasia"},{"key":"2025112417240608100_bib56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"2025112417240608100_bib57","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"de la Cruz-L\u00f3pez","year":"2019","journal-title":"Front Oncol"},{"key":"2025112417240608100_bib58","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","article-title":"Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1","volume":"145","author":"Luo","year":"2011","journal-title":"Cell"},{"key":"2025112417240608100_bib59","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cam4.210","article-title":"Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma","volume":"3","author":"Wong","year":"2014","journal-title":"Cancer Med"},{"key":"2025112417240608100_bib60","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/bjc.2015.404","article-title":"Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma","volume":"113","author":"Wong","year":"2015","journal-title":"Br J Cancer"},{"key":"2025112417240608100_bib61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025112417240608100_bib62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025112417240608100_bib63","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/brain\/aww046","article-title":"Corticosteroids compromise survival in glioblastoma","volume":"139","author":"Pitter","year":"2016","journal-title":"Brain"},{"key":"2025112417240608100_bib64","doi-asserted-by":"crossref","first-page":"65125","DOI":"10.18632\/oncotarget.11372","article-title":"Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"2025112417240608100_bib65","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3390\/cancers12103016","article-title":"Tumor Treating Fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics","volume":"12","author":"Voloshin","year":"2020","journal-title":"Cancers"},{"key":"2025112417240608100_bib66","doi-asserted-by":"crossref","article-title":"Abstract 2011: Tumor treating fields induce cellular and morphologic changes including disruption of intercellular communication networks in malignant pleural mesothelioma","author":"Sarkari","DOI":"10.1158\/1538-7445.AM2021-2011"},{"key":"2025112417240608100_bib67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41420-018-0130-x","article-title":"Tumor treating fields increases membrane permeability in glioblastoma cells","volume":"4","author":"Chang","year":"2018","journal-title":"Cell Death Discov"},{"key":"2025112417240608100_bib68","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3390\/cancers13092283","article-title":"Permeabilizing cell membranes with electric fields","volume":"13","author":"Aguilar","year":"2021","journal-title":"Cancers"},{"key":"2025112417240608100_bib69","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-5193(89)80075-X","article-title":"Bioelectrorheological model of the cell. 1. Analysis of stresses and deformations","volume":"137","author":"Pawlowski","year":"1989","journal-title":"J Theor Biol"},{"key":"2025112417240608100_bib70","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/molecules23113044","article-title":"A review on Electroporation-based intracellular delivery","volume":"23","author":"Shi","year":"2018","journal-title":"Molecules"},{"key":"2025112417240608100_bib71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-biophys-052118-115451","article-title":"Membrane electroporation and electropermeabilization: mechanisms and models","volume":"48","author":"Kotnik","year":"2019","journal-title":"Annu Rev Biophys"},{"key":"2025112417240608100_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-brain barrier: From physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol Rev"},{"key":"2025112417240608100_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40139-016-0106-6","article-title":"Tight Junctions and the Tumor Microenvironment","volume":"4","author":"Salvador","year":"2016","journal-title":"Curr Pathobiol Rep"},{"key":"2025112417240608100_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev.neuro.22.1.11","article-title":"The cell biology of the blood-brain barrier","volume":"22","author":"Rubin","year":"1999","journal-title":"Annu Rev Neurosci"},{"key":"2025112417240608100_bib75","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","article-title":"Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo","volume":"41","author":"Giladi","year":"2014","journal-title":"Semin Oncol"},{"key":"2025112417240608100_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jneuroim.2006.06.019","article-title":"Differential susceptibility of cerebral and cerebellar murine brain microvascular endothelial cells to loss of barrier properties in response to inflammatory stimuli","volume":"179","author":"Silwedel","year":"2006","journal-title":"J Neuroimmunol"},{"key":"2025112417240608100_bib77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2011.10.045","article-title":"Addition of NMDA-receptor antagonist MK801 during oxygen\/glucose deprivation moderately attenuates the upregulation of glucose uptake after subsequent reoxygenation in brain endothelial cells","volume":"506","author":"Neuhaus","year":"2012","journal-title":"Neurosci Lett"},{"key":"2025112417240608100_bib78","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fncel.2014.00352","article-title":"The pivotal role of astrocytes in an in vitro stroke model of the blood-brain barrier","volume":"8","author":"Neuhaus","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"2025112417240608100_bib79","doi-asserted-by":"crossref","first-page":"569881","DOI":"10.3389\/fphys.2020.569881","article-title":"Kidney Ischemia\/reperfusion injury induces changes in the drug transporter expression at the Blood-brain barrier","volume":"11","author":"Burek","year":"2020","journal-title":"Front Physiol"},{"key":"2025112417240608100_bib80","doi-asserted-by":"crossref","first-page":"573950","DOI":"10.3389\/fncel.2020.573950","article-title":"Neuroprotective effects of isosteviol sodium in murine brain capillary cerebellar endothelial cells (cerebEND) After Hypoxia","volume":"14","author":"R\u00f6sing","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"2025112417240608100_bib81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00418-021-01992-z","article-title":"Senescence and associated blood-brain barrier alterations in vitro","volume":"156","author":"Salvador","year":"2021","journal-title":"Histochem Cell Biol"},{"key":"2025112417240608100_bib82","doi-asserted-by":"crossref","article-title":"Tumor treating fields effects on the blood-brain barrier in vitro and in vivo","author":"Salvador","DOI":"10.1200\/JCO.2020.38.15_suppl.2551"},{"key":"2025112417240608100_bib83","article-title":"Breaching the Blood-Brain Barrier via Tumour Treating Fields","author":"Salvador","year":"2021"},{"key":"2025112417240608100_bib84","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000137713","article-title":"A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and\/or metastatic solid tumors","volume":"31","author":"Salzberg","year":"2008","journal-title":"Onkologie"},{"key":"2025112417240608100_bib85","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer"},{"key":"2025112417240608100_bib86","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with Tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A Randomized Clinical Trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"2025112417240608100_bib87","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"2025112417240608100_bib88","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","article-title":"Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial","volume":"141","author":"Toms","year":"2019","journal-title":"J Neurooncol"},{"key":"2025112417240608100_bib89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/cns-2016-0049","article-title":"Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial","volume":"6","author":"Kesari","year":"2017","journal-title":"CNS Oncol"},{"key":"2025112417240608100_bib90","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025112417240608100_bib91","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-CT201","article-title":"Final results of Phase II STELLAR trial: TTFields with chemotherapy in unresectable malignant pleural mesothelioma","volume":"79","author":"Ceresoli","year":"2019","journal-title":"Cancer Res"},{"key":"2025112417240608100_bib92","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","article-title":"Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study","volume":"19","author":"Rivera","year":"2019","journal-title":"Pancreatology"},{"key":"2025112417240608100_bib93","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ygyno.2018.07.018","article-title":"Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study","volume":"150","author":"Vergote","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025112417240608100_bib94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.lungcan.2013.06.025","article-title":"A phase I\/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer","volume":"81","author":"Pless","year":"2013","journal-title":"Lung Cancer"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-22-0887\/3180540\/can-22-0887.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/82\/20\/3650\/3213011\/3650.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/82\/20\/3650\/3213011\/3650.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:25:47Z","timestamp":1764023147000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/82\/20\/3650\/709639\/The-Mechanisms-of-Action-of-Tumor-Treating"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":94,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,7,15]]},"published-print":{"date-parts":[[2022,10,17]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-22-0887","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22431801.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6513993.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6513993","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22431801","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]}}}